drugset / Trial / NCT05552651
Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The objective is to investigate the efficacy and safety of envafolimab combined with chemotherapy for preoperative neoadjuvant therapy in patients with resectable esophageal squamous cell carcinoma
Timeline
- Start
- 2022-09-20
- Primary completion
- 2023-12-20
- Completion
- 2023-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Envafolimab | Monoclonal antibody | 300 mg | Subcutaneous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | 130 mg/m2 | Intravenous |